Formatech fills for Phase I Cellceutix study

Drug formulator Formatech of Andover, MA, will prep Kevetrin, a candidate for the treatment of drug-resistant cancers, for a Cellceutix Phase I study. The small-molecule substance will take the form of a lyophilized powder for reconstitution in saline solution. Terms were not disclosed. Formatech also runs the Fillanthropy program, through which Tracon Pharma recently received an aseptic fill and finish donation for one lot of its TRC102 cancer treatment candidate. Cellceutix release | Tracon announcement

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.